Further compared to ccRCC and Mit family translocation RCC (tRCC), CDC had the significantly highest FUBP1 protein abundance and ribosome pathway score (Fig. 3L and Fig. S2K), indicating that the pharmacological targeting of FUBP1 might offer a promising therapeutic approach for CDC patients. Here, FUBP1 is linked to nonpapillary renal cell carcinoma.